Skip to content
Study details
Enrolling now

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Inova Health Care Services
NCT IDNCT07023666ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

100

Study length

about 1.7 years

Ages

18+

Locations

2 sites in VA

What this study is about

Researchers are testing whether early screening for heart complications and treatment for iron overload can prevent heart problems and reduce hospitalizations in people with sickle cell disease. The trial will involve using medications like deferasirox, deferiprone, or deferoxamine, along with tests such as echocardiography and electrocardiograms (ECG).

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Deferasirox
  • 2.Take Deferiprone
  • 3.Take Deferoxamine
  • +2 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralOral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

deferasirox, deferiprone, deferoxamine

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Incidence of Hospitalization for Sickle Cell Disease Related Complications, Length of Stay for SCD-Related Complications

Devices

diagnostic